Head-to-head evidence
AZD6234 vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
AZD6234
Developed by AstraZeneca
NCT06595238 · Phase 2 · completed
Randomized, quadruple-blind, placebo-controlled Phase 2 trial in 262 participants with obesity or overweight; primary endpoint Percent change in body weight from baseline to week 26. Completed December 2025; numerical results not yet posted to the registry, so the grade is the design ceiling for a completed controlled study without results.
Next expected readout: October 2026 · NCT07017179 (registry estimate)
MET-233i
Developed by Pfizer
NCT07022977 · Phase 1 · completed
Participants were randomly assigned to MET233 or a matching placebo, with everyone blinded to the assignment, which is a sound safety-testing design. However, the trial's main measure was side-effect occurrence rather than weight loss, which was only a secondary measure, and results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD6234's landscape · MET-233i's landscape